Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MACH 2 – Magnesium orotate in severe congestive heart failure – Part 2
2016-004600-53Phase 2Completed
- Sponsor
- Wörwag Pharma
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) and heart failure (HF) comparing Magnesium orotate with Placebo (2 arms). Primary endpoint: NT-proBNP level. Started Jun 2017; status: completed.
02
Drugs
magnesium orotate
03
Conditions
heart failure with reduced ejection fraction (HFrEF)heart failure (HF)
Beyond the preview
Go deeper on 2016-004600-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004600-53.